|
When I spoke with Dr. Pegram at UCLA, he specifically said that for responders the Tykerb had a very high rate of success in preventin new brain lesions, and that the success rate in decreasing the size of existing lesions was in the single digits.
So some responders even see reduction in size in lesions already there. Tykerb and Xeloda do cross the BBB, that was evident in the clinical trials. You can do a search and get access to the trial results for further evidence.
|